Bridgebio Pharma earnings were -$724.9M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest BBIO earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$192.9M, up 5.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BBIO reported annual earnings of -$724.9M, with 35.3% growth.
What were Bridgebio Pharma's earnings last quarter?
On BBIO's earnings call on Invalid Date, Bridgebio Pharma (NASDAQ: BBIO) reported Q4 2025 earnings per share (EPS) of -$0.99, up 30.28% year over year. Total BBIO earnings for the quarter were -$192.86 million. In the same quarter last year, Bridgebio Pharma's earnings per share (EPS) was -$1.42.
As of the last Bridgebio Pharma earnings report, Bridgebio Pharma is currently losing money. Bridgebio Pharma's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$724.93 million, a 35.31% increase year over year.
What was BBIO's earnings growth in the past year?
As of Bridgebio Pharma's earnings date in Invalid Date, Bridgebio Pharma's earnings has grown year over year. BBIO earnings in the past year totalled -$724.93 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.